In the news:
Amgen says no concerns around weight loss drug's bone density data after stock falls - Stocks making the biggest moves midday: Rivian, Cava, Rocket Lab, Amgen and more - Amgen set to open new tech centre in Hyderabad by end of year - Amgen to open new tech and innovation center in Hyderabad by end of 2024 - Stocks making the biggest moves premarket: Disney, Airbnb, Rivian, Amgen and more - FDA approves Amgen's treatment for most deadly form of lung cancer - Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance - Amgen teased trial results for its potential Ozempic competitor -- and the stock surged 13% - Amgen Shares Soar on Obesity Drug Progress - Stocks making the biggest moves premarket: Apple, Amgen, Cloudflare and more
Amgen
Save
ShareKey facts
- city: Thousand Oaks
- state: CA
- country: United States
- sector: Health Care
- foundation year: 1980
- industry: Pharmaceuticals
- CEO: Robert A. Bradway
Classified as: organization
Summary
Amgen is a company. It is located in Thousand Oaks, the United States and was founded in 1980. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Business
Amgen is one of the companies in the United States, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Assets: 61.2B $
- Debt: 36.9B $
- Employees: 24,200 people
- Free cash flow: 7.4B $
- Market cap: 138B $
- Profits: 5.9B $
- Revenues: 26.3B $
Stocks from Amgen
Explore more on business
Talking Points:
- AmgenA Worldwide Pioneer in Biotechnology
- Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
- Patients. They're why we develop and manufacture innovative human therapeutics to treat serious diseases. Community Guidelines: https://t.co/YlIOJSHFPG
- #WeareBiotech | Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Learn more about talking points